Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Alpine Immune Sciences, Inc. ALPN
$8.00
+$0.23 (2.83%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
376051872.00000000
-
week52high
9.89
-
week52low
4.82
-
Revenue
30064000
-
P/E TTM
-6
-
Beta
1.25847700
-
EPS
-1.79000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 21 дек 2020 г. | |
| Cowen & Co. | Outperform | 26 авг 2020 г. | |
| Piper Sandler | Overweight | Overweight | 12 авг 2020 г. |
| PiperJaffray | Overweight | 27 сент 2018 г. | |
| Oppenheimer | Outperform | Outperform | 29 июн 2018 г. |
| Oppenheimer | Outperform | Outperform | 25 окт 2022 г. |
| SVB Leerink | Outperform | 21 ноя 2022 г. | |
| Morgan Stanley | Overweight | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Sandler Andrew Seth | A | 50000 | 50000 | 05 янв 2023 г. |
| Rickey James Paul | A | 109000 | 109000 | 04 янв 2023 г. |
| GOLD MITCHELL | A | 350000 | 350000 | 04 янв 2023 г. |
| PENG STANFORD L | A | 150000 | 150000 | 04 янв 2023 г. |
| Thompson Peter A. | A | 10000 | 10000 | 03 янв 2023 г. |
| Topper James N | A | 10000 | 10000 | 03 янв 2023 г. |
| Cui Xiangmin | A | 10000 | 10000 | 03 янв 2023 г. |
| CONWAY ROBERT E | A | 10000 | 10000 | 03 янв 2023 г. |
| Peetz Christopher | A | 10000 | 10000 | 03 янв 2023 г. |
| Hernday Natasha | A | 10000 | 10000 | 03 янв 2023 г. |
Новостная лента
Alpine Immune: Rebuilding Itself From Scratch, But Long Way To Go Before Proof
Seeking Alpha
29 мар 2023 г. в 07:37
Last year, ALPN ditched its lead program after a second patient death in a CD28 molecule, a previously notorious pathway. ALPN has started all over again, with backing from a few big pharma.
Alpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 мар 2023 г. в 19:41
Alpine Immune Sciences, Inc. (NASDAQ:ALPN ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng - President, Head of R&D Paul Rickey - CFO Conference Call Participants Mike Ulz - Morgan Stanley Tara Bancroft - Cowen Mark Breidenbach - Oppenheimer Joe Pantginis - H.C. Wainwright Operator Welcome to the Alpine Immune Sciences Fourth Quarter 2022 Earnings Call.
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
23 мар 2023 г. в 19:03
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
Business Wire
20 мар 2023 г. в 16:30
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the International Society of Nephrology World Congress of Nephrology (WCN).
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
Business Wire
16 мар 2023 г. в 17:30
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc.